Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer

Abstract

indicate an inverse relation between ER expression levels and ixabepilone sensitivity. Neoadjuvant ixabepilone demonstrated promising activity and a manageable safety profile in patients with invasive breast tumors.